RXRX
RECURSION PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.83
+8.19%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 35.81x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.24x
- Price / sales
- 37.38x
- Price / cash flow
- -5.85x
Enterprise value
- Enterprise value
- $1.6B
- EV / sales
- 28.56x
- EV / EBITDA
- -3.52x
- EV / EBIT
- -2.88x
- Market cap
- $2.1B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026